PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Anakena Group

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

PharmaPromo Launches New Website Fluoxetine.com - Pharmapromo launches the most extensive reference website on the generic medication fluoxetine, aimed at both consumers and pharmaceutical and healthcare industry professionals - PharmaPromo.com
PharmaPromo Launches New Website Fluoxetine.com

 

NewswireToday - /newswire/ - Barcelona, Spain, 2006/08/04 - Pharmapromo launches the most extensive reference website on the generic medication fluoxetine, aimed at both consumers and pharmaceutical and healthcare industry professionals - PharmaPromo.com .

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

PharmaPromo, the owner of a major network of over 250 websites dedicated to generic medications, today announced the launch of the website fluoxetine. This unique medication website provides highly relevant and comprehensive information on the generic drug fluoxetine, more commonly known by its brand names Prozac®, Prozac Weekly® and Sarafem®.

Fluoxetine is used to treat depression and mental health conditions that currently affect over 15 million Americans. Over the last decade the global antidepressant medication market has seen an extraordinary growth and currently holds the position of the third leading drug class by prescription revenue. However, with only ten leading drugs on the market generating global sales of $14 billion in 2004 and nine out of these ten facing loss of patents between 2006 and 2011, the dynamics of this market are set to undergo considerable changes with very few blockbuster drugs entering the market. As generic competition intensifies, companies need to carefully re-examine their strategies if they wish to protect their market share.

Fluoxetine.com is set to become the leading reference point for both consumers and pharmaceutical industry professionals seeking reliable and accurate information in a market that is facing new challenges. It provides extensive product information and up-to-date resources, together with exclusive insider industry news on which companies and organizations are playing an important part in its research, development, production and promotion.

For consumers, this website provides access to relevant information and covers key topics regarding depression, obsessive-compulsive disorder, eating disorders such as bulimia nervosa, premenstrual dysphoric disorder and panic disorder. For them this medication provides a way of controlling their illness to prevent it from burdening their daily lives. Consumers are progressively being presented with a greater variety of medications that suit varying needs, both medically and economically. Fluoxetine.com is their source of accurate and detailed information about what is available on the market (either in its branded form or generic version).

From a pharmaceutical company or health organization stand point the website offers companies the opportunity to develop their corporate identity and extend their customer reach as it continues to attract an increasing amount of regular and highly targeted users. All visitors have the opportunity to take part in open discussion forums and share their own knowledge and experiences with other consumers. This hands-on approach by regular patients and pharmacists who have had experience using fluoxetine will create an expansive community and interactive meeting point.

About PharmaPromo

PharmaPromo is one of several online business divisions provided by the Anakena Group, a European company located in Barcelona, Spain. Founded in April 1999, the company is dedicated to developing innovative Internet strategies for specific niches including the pharmaceutical market. It focuses on providing a unique service for patients, and offer leading pharmaceutical companies, manufacturers, PBMs and healthcare professionals the most competitive solutions for strengthening the reach and frequency of their corporate message, as well as securing their company’s online presence via a highly-targeted advertising platform. The completion of fluoxetine.com adds further depth to the PharmaPromo project - covering the top-selling worldwide drugs and principal therapeutic areas – and predicts the completion of its redevelopment project by September 2006.

Editorial note: Prozac®, Prozac Weekly® and Sarafem® are registered trademarks of Eli Lilly and Company.

Business Contact:
Richard Cottrell, B2B Development Manager
T: +34 93 183 3330 / El: richard[.]pharmapromo.com / Skype: pharmapromo

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Anakena Group

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


PharmaPromo Launches New Website Fluoxetine.com

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Louise Wanstall - PharmaPromo.com 
+34 93 272 03 60 louise[.]pharmapromo.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Anakena Group securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Anakena Group / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)